文献速递神经肿瘤

小分子介导的核糖体生物合成破坏与FGFR抑制剂协同抑制胶质瘤细胞生长

Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth.
PubMed 文献 · Neuro Oncol · 2023-01-01

该研究分析胶质瘤患者转录组数据发现核糖体生物合成(RiBi)速率与组织学分级正相关,并在成人及儿童高级别胶质瘤细胞系和斑马鱼移植模型中测试RNA聚合酶I转录抑制剂BMH-21,发现其降低细胞活力、诱导凋亡并抑制移植瘤生长,且与替莫唑胺及FGFR抑制剂厄达替尼协同。

要点

  • 胶质瘤患者转录组数据显示RiBi速率与组织学分级正相关。
  • BMH-21降低胶质瘤细胞活力、诱导凋亡并损害斑马鱼移植瘤生长。
  • BMH-21与替莫唑胺或FGFR抑制剂厄达替尼联用具有协同效应。

核心结论

  • 本研究提出RiBi抑制可作为胶质瘤未来可行的治疗策略,并揭示RiBi抑制后细胞反应与FGFR通路相关,具有潜在转化价值。

研究设计与样本

  • 分析胶质瘤患者转录组数据中RiBi相关过程;在成人及儿童高级别胶质瘤细胞系和斑马鱼移植模型中测试BMH-21;通过转录组学、细胞周期分析和活力测定评估细胞表型;进行化学协同筛选以识别增强BMH-21效果的药物。

主要发现

  • 公开的胶质瘤患者转录组数据显示RiBi速率与组织学分级呈正相关。
  • BMH-21降低胶质瘤细胞活力、诱导凋亡并损害斑马鱼中移植的胶质瘤细胞生长。
  • BMH-21与替莫唑胺联用增强细胞毒性效应。
  • BMH-21与化学协同筛选中的顶级命中药物FGFR抑制剂厄达替尼协同。
  • 使用BMH-21、POLR1A siRNA或放线菌素D抑制RiBi揭示FGFR-FGF2通路参与;BMH-21下调FGFR1和SOX2水平,而FGF2被诱导并从核仁释放。

关键数值与推荐

  • BMH-21为RNA聚合酶I转录的小分子抑制剂。
  • 厄达替尼为FGFR抑制剂,是化学协同筛选中的顶级命中药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade gliomas are malignant brain tumors characterized by aggressiveness and resistance to chemotherapy. Prognosis remains dismal, highlighting the need to identify novel molecular dependencies and targets. Ribosome biogenesis (RiBi), taking place in the nucleolus, represents a promising target as several cancer types rely on high RiBi rates to sustain proliferation. Publicly available transcriptomics data of glioma patients revealed a positive correlation between RiBi rates and histological grades. We, therefore, hypothesized that glioma cells could be susceptible to RiBi inhibition. METHODS: Transcriptomics data from glioma patients were analyzed for RiBi-related processes. BMH-21, a small molecule inhibitor of RNA pol I transcription, was tested in adult and pediatric high-grade glioma cell lines and a zebrafish transplant model. Cellular phenotypes were evaluated by transcriptomics, cell cycle analysis, and viability assays. A chemical synergy screen was performed to identify drugs potentiating BMH-21-mediated effects. RESULTS: BMH-21 reduced glioma cell viability, induced apoptosis, and impaired the growth of transplanted glioma cells in zebrafish. Combining BMH-21 with TMZ potentiated cytotoxic effects. Moreover, BMH-21 synergized with Fibroblast Growth Factor Receptor (FGFR) inhibitor (FGFRi) Erdafitinib, a top hit in the chemical synergy screen. RiBi inhibition using BMH-21, POLR1A siRNA, or Actinomycin D revealed engagement of the FGFR-FGF2 pathway. BMH-21 downregulated FGFR1 and SOX2 levels, whereas FGF2 was induced and released from the nucleolus. CONCLUSIONS: This study conceptualizes the implementation of RiBi inhibition as a viable future therapeutic strategy for glioma and reveals an FGFR connection to the cellular response upon RiBi inhibition with potential translational value.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Zisi A, Kanellis DC, Moussaud S, et al. Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth. Neuro Oncol. 2023. PMID: 36583853. doi:10.1093/neuonc/noac286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。